# Press Release

Lund, June 25, 2019

## *Bronchodilator effect shown in vivo for the new RES030-085 substance within RESP9000*

**Respiratorius AB (publ) announces positive results from an airway study in an animal model with the patented candidate substance RES030-085 for the treatment of COPD and severe asthma. The identification of the substance RES030-085 and its patent application was previously announced in 2018. Going forward, we will group RES030-085 as well as the associated compounds in the chemical series under the project name RESP9000.**

The study was carried out by an internationally renowned contract laboratory and in an established animal model (rat) where the experimental animals were exposed to an airway contracting substance, carbamylcholine, and then the bronchodilator effect of the test substances was evaluated by measurements of the pulmonary flow resistance. The bronchodilator properties of RES030-085 (RES9000 series) have been compared with control and with RES022-125 from the RES1000 series.

Results from the study in summary

- The experiments showed that RES030-085 has a clear and statistically significant bronchodilator effect in rats compared to the control group.
- The trials did not result in any measured or observed adverse reactions at the effective dose of RES030-085.
- Furthermore, preliminary characterization studies of the chemical structure have shown that RES030-085 has a high likelihood of successful formulation as an inhaled drug.

This is the first time any of the Respiratorius substances have shown a bronchodilator effect in an in vivo model. From previous experiments on tissue samples (bronchioles) from humans and rats performed ex vivo, ie tissue samples evaluated outside the body, it is known that the bronchodilators of Respiratorius compounds are 100-fold less potent in rats compared to humans. It has therefore not been obvious that in vivo efficacy was possible in rats.

Respiratorius' new substance, RES030-085 from the RES9000 series, has a remaining patent life of over 19 years to be compared to the RES1000 series, which has 8 years of remaining patent life. Since RES030-085 is outside of the RES1000 series, it is not affected by any third-party agreements and in the case of an approved patent, market exclusivity is obtained in applied countries up to and including 2038.

The aim of Respiratorius is to prepare clinical studies with RES9000 as soon as possible, which is why additional supplements to the preclinical program have begun.

*This information is such information that Respiratorius AB (Publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on June 25, 2019.*

**For further information, please contact:**


Johan Drott
CEO Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com

Christer Fåhraeus
Chairman Respiratorius AB
+46 705-60 90 00
christer.fahraeus@respiratorius.com


Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases like cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the company portfolio also holds a project for improved diagnosis of certain cardiovascular diseases.